Objectives The treatment for COVID-19 often utilizes immune-modulating drugs. These
drugs are also used in immune mediated inflammatory diseases (IMIDs). We performed a …

Background This study applies an umbrella review approach to summarise the global
evidence on the risk of severe COVID-19 outcomes in patients with pre-existing health …

Background The COVID-19 pandemic has claimed the lives of nearly 2 million people
worldwide. 1 Following rapid sequencing of SARS-CoV-2, pharmaceutical companies and …

Background Our understanding of coronavirus disease 2019 (COVID-19) and its
implications for patients with inflammatory bowel diseases (IBD) is rapidly evolving. We …

Background And Aims The serological responses after severe acute respiratory syndrome
coronavirus 2 vaccination may be attenuated in immunocompromised individuals. The study …

The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

Background and Aims. The impact of COVID‐19 has been of great concern in patients with
inflammatory bowel disease (IBD) worldwide, including an increased risk of severe …

Severe acute respiratory syndrome coronovirus-2 (SARS-CoV-2) is the cause of the
coronavirus disease 2019 (COVID-19) pandemic. Vaccination is considered the core …

Severe COVID-19 patients present a clinical and laboratory overlap with other
hyperinflammatory conditions such as hemophagocytic lymphohistiocytosis (HLH) …

Background Poor immune responses are frequently observed in patients with inflammatory
bowel disease (IBD) receiving established vaccines; risk factors include …